About GeoVax Labs
GeoVax Labs (NASDAQ:GOVX) is a biotechnology firm focusing on developing vaccines to address infectious diseases, cancers, and for use in immunotherapy. Traded on the NASDAQ stock exchange under the ticker code (NASDAQ:GOVX), the company leverages its unique Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform to produce vaccines that induce robust immune responses. GeoVax's projects span several critical areas, including HIV, COVID-19, Zika virus, hemorrhagic fever viruses, and malaria, alongside working on therapeutic vaccines for chronic Hepatitis B infections and solid tumors. The objective of GeoVax is not only to advance public health through preventive measures against infectious diseases but also to pioneer therapeutic vaccines that could potentially transform cancer treatment paradigms.
Snapshot
Operations
Produtos e/ou serviços de GeoVax Labs
- Development of a preventive vaccine for COVID-19 using a modified vaccinia Ankara (MVA) vector platform.
- HIV vaccines aimed at preventing and treating different clades of the HIV virus.
- MVA-VLP vaccine platform targeting prevention of Zika virus infections.
- Therapeutic vaccine research focused on chronic hepatitis B infection.
- Ebola virus vaccine utilizing the MVA platform for prevention.
- Collaborative efforts in immunotherapy for solid tumor cancers, leveraging its MVA technology.
equipe executiva do GeoVax Labs
- Mr. David Alan DoddChairman, President & CEO
- Dr. Mark J. Newman Ph.D.Chief Scientific Officer
- Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Medical Officer
- Dr. Harriet Latham Robinson Ph.D.Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
- Mr. Mark W. Reynolds CPACFO & Corporate Secretary
- Mr. Thomas O'BrienVice President of Quality Systems & Compliance
- Mr. Jeffrey WelchHead of Process Development & Manufacturing Operations
- Dr. John W. Sharkey Ph.D.Vice President of Business Development